Comparative Pharmacology
Head-to-head clinical analysis: ATOMOXETINE HYDROCHLORIDE versus SUNOSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOMOXETINE HYDROCHLORIDE versus SUNOSI.
ATOMOXETINE HYDROCHLORIDE vs SUNOSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective norepinephrine reuptake inhibitor (NRI) that increases noradrenergic neurotransmission in the prefrontal cortex.
Selective dopamine and norepinephrine reuptake inhibitor; also acts as a TAAR1 agonist, increasing cAMP levels in monoamine neurons.
Initial 40 mg orally once daily; increase after minimum 3 days to 80 mg/day; maximum 100 mg/day if inadequate response after 2-4 weeks.
75 mg orally once daily upon awakening.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours in CYP2D6 extensive metabolizers; in poor metabolizers, half-life is prolonged to about 21-24 hours.
Terminal elimination half-life is approximately 9.5 hours in healthy adults; clinically relevant for once-daily dosing.
Primarily renal: approximately 80% of a dose is excreted in urine, with 2-3% as unchanged drug; 17% fecal.
Primarily renal elimination (approximately 95% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%.
Category C
Category C
Norepinephrine Reuptake Inhibitor
Dopamine and Norepinephrine Reuptake Inhibitor